Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.

Genome medicine - 30 Oct 2017

Li Shuyu D, Ma Meng, Li Hui, Waluszko Aneta, Sidorenko Tatyana, Schadt Eric E, Zhang David Y, Chen Rong, Ye Fei

Abstract excerpt

BACKGROUND: Next-generation sequencing (NGS) of cancer gene panels are widely applied to enable personalized cancer therapy and to identify novel oncogenic mutations. METHODS: We performed targeted NGS on 932 clinical cases of non-small-cell lung cancers (NSCLCs) using the Ion AmpliSeq™ Cancer Hotspot panel v2 assay. RESULTS: Actionable mutations were identified in 65% of the cases with available targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Germ-Line Mutation

Share to Immunotherapy

Share to Janus Kinase 2

Share to Janus Kinase 3

Share to Programmed Cell Death 1 Receptor

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 29082853
DOI: 10.1186/s13073-017-0478-1
PMCID: PMC5662094

Genes

JAK2
JAK3

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.PMID 29082853Read ↗

Mining for JAK-STAT mutations in cancer.Semantic proximity Read ↗

Biomarker testing for advanced lung cancer by next-generation sequencing; a valid method to achieve a comprehensive glimpse at mutational landscapeSemantic proximity Read ↗

Tumor molecular profiling of NSCLC patients using next generation sequencing.Semantic proximity Read ↗

Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted TherapiesSemantic proximity Read ↗

Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.Semantic proximity Read ↗

Whole-exome sequencing analysis of NSCLC reveals the pathogenic missense variants from cancer-associated genes.Semantic proximity Read ↗

Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg casesSemantic proximity Read ↗

Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.Semantic proximity Read ↗

MET-Oncogenic and JAK2-Inactivating Alterations Are Independent Factors That Affect Regulation of PD-L1 Expression in Lung Cancer.Semantic proximity Read ↗

Non-small cell lung cancers with isocitrate dehydrogenase 1 or 2 (IDH1/2) mutations.Semantic proximity Read ↗

Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Semantic proximity Read ↗

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.